Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
The childhood forms of polycystic kidney disease are autosomal recessive polycystic kidney disease and nephronophthisis. In animal models of these diseases, characterised by a defect in urine concentration progressing to renal failure, the selective vasopressin receptor type 2 antagonist OPC-31260 halted the progression or even caused regression of the established disease. Vasopressin receptor type 2 antagonists should proceed to clinical trial for these polycystic kidney diseases.
Doggrell
Sheila A
SA
Doggrell Biomedical Communications, Auckland, New Zealand. s_doggrell@yahoo.com
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007690:Polycystic Kidney Diseases / Q000188:drug therapy*
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; C076251:mozavaptan